12. Is the response to therapy related to HBV genotypes?

So this is something that may come into our routine practice, there’s beginning to be some early reports that at least in the case of interferon, in Caucasians, A responds better than D, and B responds better than C for interferon therapy. But for lamivudine therapy, there was no difference in the response rate, nor were there in the adefovir pivotal trials, so genotype did not predict response to therapy.